Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06902974 · ClinicalTrials.gov registry record · Phase 2
Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD
A Phase 2 study, sponsored by Sunstone Medical.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT06902974 is a Phase 2 study that is actively recruiting participants, run by Sunstone Medical. The registered enrollment target is 70 participants.
The verdict
NCT06902974, a Phase 2 study, is actively recruiting participants, sponsored by Sunstone Medical.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).
Interventions
- DRUG Psilocybin 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-05-23 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06902974
The ClinicalTrials.gov registry entry for NCT06902974 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunstone Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin 25 mg is the first listed.
NCT06902974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06902974 about?
NCT06902974 is a clinical study titled "Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD". A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).
What is the current status of trial NCT06902974?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2026-05-23. Estimated completion is 2028-05.
What interventions are being tested in trial NCT06902974?
The interventions under investigation include: Psilocybin 25 mg (DRUG).
Who is sponsoring clinical trial NCT06902974?
This trial is sponsored by Sunstone Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.